Diffuse large B-cell lymphoma is a serious cancer that can affect many parts of the body. For people who have never had treatment before, a new analysis of data shows that the drug zanubrutinib works very well. In this review, researchers looked at results from 1,346 patients. They found that 95 percent of those who had not received prior therapy saw their disease shrink or disappear. Even older patients saw an 90.7 percent response rate. This is important because many people with this cancer are elderly. The drug also worked well for those whose disease had spread to areas outside the lymph nodes. For people who had already tried other treatments, the drug helped 67.5 percent of patients. The follow-up period lasted an average of 31.2 months. During this time, the disease did not grow back in many of the untreated patients. Survival time for these patients had not been reached yet. For those with relapsed disease, survival lasted 21.8 months. The review did not report specific safety data or side effects in the provided text. While the results are promising, this analysis combines data from different studies. It is important to remember that every person reacts differently to medicine. Doctors will need to weigh these results against individual patient needs before making decisions.
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-AnalysisZanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Zanubrutinib shows high response rates and durable survival benefits in diffuse large B-cell lymphoma, including elderly and relapsed patients.
This comprehensive review evaluates the efficacy of zanubrutinib in treating diffuse large B-cell lymphoma across diverse patient populations. The analysis encompasses 1,346 individuals, providing robust data on treatment outcomes for both previously untreated and relapsed or refractory cases. Key metrics include overall response rates, complete response rates, progression-free survival, and overall survival.
In patients who had not received prior therapy, zanubrutinib demonstrated exceptional efficacy. The overall response rate reached 95.0%, with a complete response rate of 79.7%. Median progression-free survival was 31.2 months, while median overall survival had not been reached at the time of the analysis.
For patients with relapsed or refractory disease, the drug still provided meaningful benefits. The overall response rate was 67.5%, and the complete response rate stood at 44.7%. Median progression-free survival was 5.9 months, with a median overall survival of 21.8 months.
Subgroup analyses highlighted consistent performance in specific demographics. Elderly patients achieved an overall response rate of 90.7%, and those with extranodal involvement saw a rate of 82.3%. These findings underscore the drug's broad applicability across different clinical scenarios.
What this means for you:
Zanubrutinib showed high response rates in previously untreated diffuse large B-cell lymphoma patients. More on Diffuse Large B-Cell Lymphoma
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
CAR-T cell therapy improves progression-free survival (HR 0.55) and overall survival (HR 0.68) in R/R DLBCL
CAR-T cell therapy shows improved survival for certain blood cancers
This meta-analysis of 2150 adult patients with relapsed or refractory diffuse large B-cell lymphoma found that CAR-T cell therapy significan…
New analysis shows CAR-T cell therapy significantly improves survival and response rates for patients with relapsed or refractory DLBCL.
Impact of Body Mass Index Categories on Outcomes in Patients with DLBCL
Overweight status linked to better survival in certain lymphoma
A meta-analysis reveals that overweight status correlates with improved survival in DLBCL, while underweight status is linked to poorer clin…
Patients with diffuse large B-cell lymphoma who are overweight may have better survival outcomes than those who are underweight.
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
View Original Abstract ↓
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, and previous studies have indicated the potential of zanubrutinib in the treatment of DLBCL. This meta-analysis aims to evaluate the efficacy of zanubrutinib in DLBCL patients and further explore potential differences in treatment effects across diverse patient subgroups.
METHODS: A systematic literature search was conducted using two major databases (PubMed and Embase) and four key conference websites to ensure comprehensive coverage of relevant studies. Key outcomes included overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS) and overall survival (OS).
RESULTS: A total of 47 studies involving 1346 patients were included in the meta-analysis. Zanubrutinib in previously untreated patients with DLBCL showed a pooled CRR of 79.7% (95% CI 72.7%-86.7%) and a pooled ORR of 95.0% (95% CI 92.6%-97.4%), while the pooled CRR was 44.7% (95% CI 32.4%-56.9%) and the pooled ORR was 67.5% (95% CI 58.0%-77.0%) for the relapsed/refractory patients. For patients with extranodal involvement and elderly patients, the pooled ORRs were 82.3% (95% CI 75.7%-88.9%) and 90.7% (95% CI 85.7%-95.7%), respectively. Pooled analysis of survival curves showed that among previously untreated patients, the median PFS was 31.2 months and median OS was not reached, while the median PFS and OS were 5.9 months and 21.8 months among relapsed/refractory patients, respectively.
CONCLUSIONS: Zanubrutinib-based regimen achieved encouraging treatment response, especially in specific subtypes of DLBCL, including double expressor, elderly, extranodal involvement, and non-GCB DLBCL.
Biomarkers and clinical factors show statistical associations with sepsis-induced coagulopathy in 37,459 patients
Your Blood May Signal a Deadly Clotting Crisis Before It Strikes
Related in Hematology
Four specific miRNAs in extracellular vesicles satisfy high-tier causality for metabolic and inflammatory regulation
Extracellular Vesicles Show Potential for Managing Metabolic Health Conditions
This systematic review evaluates the role of extracellular vesicles (EVs) in managing obesity, type 2 diabetes, MASLD, and atherosclerosis. …
New research identifies specific molecules within extracellular vesicles that may play a role in managing obesity, diabetes, and liver disea…
FDA Approves Inrebic (fedratinib) for Intermediate-2 or High-Risk Myelofibrosis
FDA approves new pill Inrebic for rare bone marrow cancer.
The FDA approved Inrebic (fedratinib) for adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis. The recommende…
The FDA approved Inrebic (fedratinib) for adults with a type of bone marrow cancer called myelofibrosis. It is a daily pill for patients wit…
FDA Approves Jakafi (ruxolitinib) for Steroid-Refractory Acute Graft-Versus-Host Disease
FDA approves Jakafi for acute graft-versus-host disease in patients 12 and older.
The FDA approved Jakafi (ruxolitinib) for treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12…
The FDA approved Jakafi (ruxolitinib) to treat acute graft-versus-host disease (aGVHD) in people aged 12 and older who do not respond to ste…
FDA Approves Vonjo (pacritinib) for Myelofibrosis with Low Platelet Counts
FDA approves new drug Vonjo for rare bone marrow cancer with low platelets.
The FDA approved Vonjo (pacritinib) for adults with intermediate or high-risk primary or secondary myelofibrosis with platelet counts below …
The FDA approved Vonjo (pacritinib) for adults with myelofibrosis who have very low platelet counts. It helps reduce spleen size. This offer…
From Other Specialties
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
Current molecular and cellular phenotypes do not yet support clinical subtype identification for recurrent pregnancy loss
New research looks at why some pregnancies end early
This mini review examines maternal-fetal interface abnormalities in patients with unexplained recurrent pregnancy loss (URPL). The authors c…
Doctors are looking for better ways to understand and treat the reasons behind repeated pregnancy loss.
TNF inhibitors may be effective for juvenile idiopathic arthritis in patients with DiGeorge syndrome
Biologic treatments show promise for children with DiGeorge syndrome
This case report and literature review examines the management of juvenile idiopathic arthritis (JIA) in children with DiGeorge syndrome (DG…
Children with both DiGeorge syndrome and juvenile idiopathic arthritis may find relief from joint pain using specific biologic medications.
mHealth apps reduce HbA1c by 0.39% in type 2 diabetes across 19 RCTs
Mobile Health Apps Help Manage Blood Sugar in Type 2 Diabetes
This meta-analysis of 19 RCTs with 2,166 participants found that mobile health (mHealth) app interventions significantly reduced HbA1c (MD -…
Using mobile health applications can help people with type 2 diabetes lower their blood sugar levels and improve their overall quality of li…